Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.8% Today

What is Intellia Therapeutics, Inc.?

NTLA (Intellia Therapeutics Inc.) is a biotechnology company focused on developing CRISPR/Cas9-based therapies for genetic diseases. The overall market for gene editing stocks is competitive and dynamic.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 5.8% on Nov 28, 2025 18:40

• Intellia's bullish movement could be attributed to the positive advancements in its in vivo pipeline, particularly the progress in the HAELO study with lonvo-z.
• The comparison with a rival company might have sparked investor interest and confidence in Intellia's potential for long-term growth.
• The anticipation of mid-2026 data and a potential filing in the same year could have fueled optimism among investors, leading to the bullish market movement for NTLA today.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?

Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.

https://www.zacks.com/stock/news/2797166/can-ntlas-in-vivo-pipeline-drive-long-term-growth-amid-rivalry

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.

https://www.zacks.com/stock/news/2796337/beam-vs-ntla-which-gene-editing-stock-holds-more-potential

Trending Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Up 7.3% Today

Western Digital Corporation ($WDC) Stock Forecast: Up 5.2% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 5.3% Today

Omnicom Group Inc. ($OMC) Stock Forecast: Up 5.0% Today

Cognex Corporation ($CGNX) Stock Forecast: Down 4.6% Today

Dayforce, Inc. ($DAY) Stock Forecast: Up 0.3% Today

Uber Technologies Inc. ($UBER) Stock Forecast: Down 8.2% Today

XRP ($XRP) Crypto Forecast: Down 5.0% Today

Manhattan Associates, Inc. ($MANH) Stock Forecast: Down 2.6% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Up 5.0% Today

Intellia Therapeutics, Inc. Price History

22.09.2025 - NTLA Stock was down 6.5%

• The bearish movement in NTLA's stock today could be due to concerns about the competition in the gene editing space.
• Investors may be cautious about the company's ability to maintain a competitive edge in the market, especially with the focus on its in vivo pipeline for long-term growth.
• The market might be reacting to uncertainties surrounding the success and commercialization of Intellia's late-stage gene-editing therapies, lonvo-z and nex-z.
• Overall, the negative market sentiment towards NTLA today could be influenced by doubts about the company's future growth prospects amidst a competitive landscape in the gene editing industry.

28.09.2025 - NTLA Stock was down 6.8%

• The downward movement in NTLA stock could be tied to the overall negative sentiment in the biotechnology sector, possibly influenced by the recent downgrade of Boot Barn Holdings Inc. by a prominent Wall Street analyst.
• This shift in analyst perspective may have impacted investor trust in the sector, resulting in a sell-off of NTLA shares.
• Investors appear to be exercising caution regarding the future potential of gene editing technologies, including CRISPR/Cas9, in light of recent analyst actions and broader market patterns.

08.09.2025 - NTLA Stock was up 25.1%

• Analysts on Wall Street foresee a 63.7% upside potential for NTLA, reflecting favorable sentiment towards the stock.
• The company disclosed inducement grants in line with Nasdaq Listing Rule 5635, highlighting efforts to attract top talent and foster innovation.
• The rising trend in earnings estimate revisions may have contributed to the stock's bullish performance.
• Overall, positive developments and optimistic analyst projections appear to have propelled the strong bullish trend in Intellia Therapeutics' stock today.

30.09.2025 - NTLA Stock was down 9.8%

• Intellia Therapeutics (NTLA) stock saw a significant drop in after-hours trading subsequent to the FDA's decision to place a clinical hold on some of its Investigational New Drug applications.
• The regulatory setback from the FDA has likely caused concerns among investors regarding potential delays in the company's drug development pipeline and its financial implications.
• This news prompted a sell-off as investors reassessed Intellia Therapeutics' short-term outlook, leading to a notable decrease in NTLA stock price.
• The bearish trend in NTLA stock may continue until there is more clarity on the FDA's issues and the company's plan to address them, underscoring the significance of regulatory risks in the biotech sector.

09.09.2025 - NTLA Stock was up 5.1%

• NTLA experienced a significant increase of 19.7% in its shares, accompanied by above-average trading volume.
• Analysts from Wall Street are optimistic about NTLA, projecting a potential upside of 63.7% for the stock, reflecting favorable market sentiment.
• Recent changes in earnings estimates for Intellia Therapeutics may have contributed to the price surge, hinting at further growth in the short term.
• The company disclosed the provision of inducement grants under Nasdaq Listing Rule 5635 (c)(4), potentially enhancing investor confidence in the company's future prospects.

11.10.2025 - NTLA Stock was down 5.6%

• NTLA stock dropped despite posting a reduced loss in Q3, attributed to challenges in its pipeline and retracting guidance amidst FDA investigation in amyloidosis patients.
• Revenue for the quarter fell short of expectations, likely impacting investor sentiment negatively.
• Analysts revising their projections for the stock to a more pessimistic view also contributed to the decline in NTLA shares.
• Uncertainties related to the FDA investigation and the company's pipeline setbacks appeared to outweigh any positive aspects of the earnings report, resulting in a significant drop in stock price.

28.10.2025 - NTLA Stock was up 5.8%

• Intellia's bullish movement could be attributed to the positive advancements in its in vivo pipeline, particularly the progress in the HAELO study with lonvo-z.
• The comparison with a rival company might have sparked investor interest and confidence in Intellia's potential for long-term growth.
• The anticipation of mid-2026 data and a potential filing in the same year could have fueled optimism among investors, leading to the bullish market movement for NTLA today.

28.10.2025 - NTLA Stock was up 5.4%

• The bullish movement in NTLA could be attributed to the company's recent positive developments in its gene editing therapies, outshining its competitor BEAM.
• Investors might be favoring NTLA over BEAM due to its specific pipeline advancements and promising study results, leading to increased confidence in NTLA's potential for growth.
• This market movement suggests that NTLA's strategic positioning and progress in the gene editing sector are resonating well with investors, driving up the stock price significantly.

07.10.2025 - NTLA Stock was down 24.0%

• NTLA disclosed a Q3 loss and revenue estimates were not met, signifying financial underperformance.
• The adverse earnings surprise and revenue shortfall probably influenced investor apprehensions and the downward trend in the stock price.
• Investors might be wary about the company's future outlook and the implications of these financial outcomes on its pipeline and growth opportunities.

07.10.2025 - NTLA Stock was down 27.2%

• A recent decrease in Q3 losses did not prevent a significant bearish trend in NTLA stock. This was notably influenced by the company retracting guidance on a crucial pipeline milestone and encountering FDA scrutiny regarding amyloidosis patients.
• Despite the company's Q3 loss and revenue missing estimates, investor confidence dwindled further.
• Concerns over FDA scrutiny and uncertainty about the company's milestone achievements may have spurred a wave of sell-offs for NTLA stock.
• Investors are likely reassessing NTLA's future based on financial performance and regulatory obstacles, consequently amplifying the downward pressure on the stock price.

12.10.2025 - NTLA Stock was up 5.3%

• NTLA reported a narrowed Q3 loss, but the stock declined after the company withdrew guidance on a key pipeline milestone, sparking concerns about FDA scrutiny in amyloidosis patients.
• The company fell short of revenue expectations for the quarter, which may have initially contributed to negative market sentiment.
• Despite these setbacks, investors have responded positively to the progress and potential of NTLA's CRISPR-based therapies, driving the stock's upward movement today.
• The market appears to be reevaluating Intellia Therapeutics' long-term outlook, taking into account the potential impact of their innovative genetic disease treatments despite short-term challenges.

14.10.2025 - NTLA Stock was down 5.4%

• The company is currently dealing with FDA clinical holds on significant studies, causing uncertainty and negative sentiment among investors.
• Setbacks in the pipeline, particularly in ATTR studies, have raised concerns about Intellia's short-term outlook.
• The delay in crucial data concerning HAE treatment (lonvo-z) has contributed to the downward trend in NTLA stock.
• Regulatory challenges and uncertainties surrounding key data releases have fueled the substantial bearish movement in NTLA stock today.